Rheumatology biologic switching settles into patterns
Real-world data on rheumatology biologic switching is now mature enough to inform first-line and switch decisions.
Rheumatology has had a multi-class biologic shelf for years; switching data is now mature enough to read. JAK after biologic failure is a recognised pattern; IL-23 after TNF failure is becoming standard in axSpA. The first-line conversation is increasingly cost-sensitive.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.